Skip to main content

Table 4 Summary of baseline demographic and clinical characteristics comparing treatment (Floseal® (Baxter, USA)) to control (traditional packing methods)

From: Management of Persistent Epistaxis Using Floseal Hemostatic Matrix vs. traditional nasal packing: a prospective randomized control trial

  Treatment (Floseal) (N = 13) Control
(N = 13)
Z-score p-valuea,b
Age 59.0 55.1 0.5128 0. 6101a
Gender (Male) 8 (61.5%) 6 (46.2%) NA 0.6951b
ASA 2 (15.4%) 3 (23.1%) NA 1.000b
CCI 2.3 2.3 −0.1282 0.8966a
  1. a α = 0.05, significant results in bold using unpaired Mann-Whitney U test, CCI Charlson Comorbidity Index, ASA Aspirin 81 mg po daily
  2. b α = 0.05, significant results in bold using Fisher’s exact test